Tag Archives: clinical trial

Neurocrine and the Rogue Site

Neurocrine Biosciences has released the PhII results for NBI-98854, their VMAT2 inhibitor for Tardive Dyskinesia. The Company reported that a single site (of the eight US sites involved) threw off the overall data analysis because their AIMS testing scores did … Continue reading

Posted in Biotech | Tagged , , | Leave a comment